GBV is a national health care contract sales organization (CSO) that represents medical companies of all sizes. GBV's current client base and sales emphasis is focused on the emerging regenerative medicine industry and the related products and services including: biologics (amniotic tissue, PRP, BMAC), nitric oxide products, instrumentation, laboratory and surgical diagnostics, revenue cycle management and patient financing. GBV's 100+ senior sales executives grow our clients' customer base and revenue by leveraging their established physician, practice and health care executive relationships. Our methodology helps clients from start ups to Fortune 500 companies, find, qualify and close more deals; develop strategic joint ventures; identify, staff, train and manage their sales team; and ultimately move more profitable opportunities through their sales pipeline faster. Our clients' customers include hospitals, pharmacies, long-term care facilities, surgery centers and orthopedic, spine, pain management, neurology, wound care, DPM, medspa and anti-aging physicians. GBV works with clients to build a key set of strengths in their respective markets:•Work with clients to create a corporate/product competitive advantage(s) and/or high barrier to entry (cost/regulatory, etc.) in their specific market segment;•Create product/service solutions that have the potential to generate annuity (automatic up-sell, resell, reorder, subscription) revenue; •Dramatically drive down existing sales cycle - typically 1-6 months;•Train clients to gain executive level access and effectively communicate unique high level value proposition;•Use our broad industry experience to help clients achieve above average industry margins;• In every situation, we stress the importance of maintaining impeccable character within client's leadership and sales teams.

Insight Diagnostics is a CAP accredited clinical reference lab based in Franklin, TN (Greater Nashville). Insight has recently introduced the 1st Genetically Enhanced Medication Monitoring (GEMM) solution. Insight combined 2 widely used & often expensive lab tests - Definitive Urine Drug Test (UDT) and a Pharmacogenetic (PGx) "snapshot" into one – low cost - test. GEMM reduces the potential for ADRs and lab and medication costs and improves the diagnostic and prescribing capabilities of physicians..Pain News Network article: https://www.painnewsnetwork.org/stories/2017/4/20/new-test-identifies-poor-drug-metabolizers Unique Benefits: 1) Genetically aligned medications are identified, eliminating the standard “trial and error” prescription process, saving millions of dollars currently spent on ineffective and potentially toxic medications;2) Physician/patient relationships will be improved when MDs recognize their patients have taken medications as prescribed, but are either ultra-rapid or non-metabolizer of the medication(s). All other labs’ UDT reports are often inaccurate as they lack data on the patient’s genetic ability to metabolize their medications; 3) Overall patient outcomes/satisfaction will be improved when the most effective medication is prescribed from the treatment outset;4) Patients whose genetics cause them to be poor, or ultra-rapid metabolizers of specific medications are identified and can be prescribed more appropriate opiates/pain medications, or alternative drug classes; and5) The risk of potentially deadly Adverse Drug Reactions (ADRs) and the related costly comorbidities are significantly reduced. For less than what other labs charge for an incomplete UDT test, GEMM includes a comprehensive UDT that also identifies the estimated 20% -30% of patients that generate UDT reports with false positive/negative results due to the patient’s genetics.

Responsible for developing the strategic plan and business development initiatives for Merit Laboratory Partners' three lab development & management market segments.Merit is the first and only comprehensive laboratory consulting and management firm that designs, builds and operates CLIA certified high-complexity urine toxicology and DNA laboratories for physician practices, independent reference labs and hospital systems.

RapiDemand guides and assists healthcare and IT services and software companies in developing and implementing growth strategies through mergers and acquisitions, capital raises and strategic consultation. Our approach, expertise and comprehensive methodology ensures that these strategies deliver optimum results. We guide our clients in the development of objectives, due diligence, discovery, positioning and presentation, process management, negotiating, and closing.Unlike one-dimensional investment bankers with a deal-driven approach and a focus solely on financial analysis, RapiDemand delivers critical expertise and business-level insights to all dimensions of the deal:• Due diligence and financial modeling• Detailed corporate and personnel research and competitive analysis• C-Level perspective in the evaluation of leadership and staff, including personalities, quality of people and leadership, marketability• Proprietary reporting and data review formats that streamline decision-making

• T-Systems is an $8B global IT and Network (ICT) managed services company with over 40,000 employees.• Established and managed the Midwestern U.S. sales area as the largest and most profitable market in North America. • Extensive experience conceptualizing and closing large strategic ICT outsourcing solutions for Fortune 500 companies in the healthcare, manufacturing, insurance verticals. • Developed over $150 million sales pipeline and generated over $125 million in sales of multi-year, complex ICT managed services deals to multinational Fortune 100 businesses. • Developed globally cooperative teams, focusing on large multinational businesses with operations in the United States. • Accounted for approximately 20% of all new ICT sales during my tenure.• Recognized in 2005, 2006 and 2007 as top revenue and/or profitability producer in North America.

• MediNet was the first company in the U.S. to provide public wireless Internet and email access to hospitals. MediNet's "webpad" was 1st wireless touch screen device, predating Apple's Ipad by 10 years. MediNet provides IT operational support and management of all related distributed computing and network assets. • Negotiated numerous managed services contracts with large hospital groups across the country as well as exclusive provider agreements with Group Purchasing Organizations, including MedAssets. • Worked with hospital C-Suite executives throughout the United States.

• ITP was the first manufacturer of portable, computer controlled, support surfaces designed to treat wound and burn patients. The Aeromat was recognized in the industry as the leading portable pressure relief system on the market.• Over 10 years, Aeromat sales and rentals grew to over $25M. • Had North American sales management and P&L responsibility for over 100 direct and independent representatives across the U.S. • Developed the direct and channel partner sales strategy for customers, including hospitals, nursing homes and medical equipment distributors across North America, EMEA and APAC. • Contributed to the original and subsequent product designs, global marketing and distribution strategy that led to a PE sale of the company.